to Q&A.
Great. Well, thanks for having us, Alex. Happy Veterans Day, I guess. Thanks to all of you for taking time to learn about our story. Palisade Bio is a clinical-stage company addressing inflammatory and fibrotic diseases. Our lead drug, PALI-2108, is an oral once-daily PDE4 inhibitor that's activated in the terminal ileum in the colon. Many of you probably know that there are a number of PDE4 inhibitors that have been repurposed from other inflammatory and fibrotic diseases to be used in IBD. The problem with those is that in order to push the dose high enough to be effective in IBD, it triggers a lot of adverse events. Our prodrug approach gets around those. We deliver high concentrations of drug in the terminal ileum and the colon while maintaining sustained systemic exposure and fewer adverse events and much higher tolerability.
We completed phase I studies earlier this year, at the very beginning of this year, that demonstrated that the drug is working as it was designed. We're currently in two phase II studies, one for ulcerative colitis and the other for Crohn's disease. The ulcerative colitis study has enrolled its first patient. The Crohn's study has received IND clearance, and we're in the process right now of activating sites and should be starting enrolling on that fairly soon.
Yep.
Therapeutic index with our drug, I think, gives us the optimism that we're going to be able to show improved efficacy with a good safety and tolerability profile.
Yeah, I mean, like maybe sort of at a high level, how strong is the evidence for PDE4 as a class in IBD, sort of historically with apremilast and sort of more recently with mufemilast and some of your own data as well?
Mitch, you want to take that?
Yeah, sure. I mean, so previously apremilast, which is a twice-daily generation two pan-inhibitor of PDE4, demonstrated about a 20% placebo-adjusted remission rate. More recently, in an I patient randomized study out of China, mufemilast, another PDE4 that's orally delivered at 45 mg twice daily or 60 mg twice daily, demonstrated a dose response and clinical remission rates that are arguably sort of best in indication. I think the learnings here, and that's at 44% placebo-adjusted remission. I think the learnings here are apremilast sort of underdosed, maybe appropriate for psoriasis. When you look at mufemilast and push the dose, you can get to sort of indication-leading clinical remission rates.
Yep. Maybe that leads into the design for 2108 and sort of this idea of colonic exposure and what that gets you relative to these first-gen approaches.
Yeah. The drug was specifically engineered for IBD. It came out of the Merck Frosst labs in Montreal. The question that they were trying to answer when they were designing the drug was, how can you capture the therapeutic potential of a PDE4 inhibitor while still improving the therapeutic window? Our drug starts out as an active prodrug.
It bypasses the upper GI tract before it is activated. It is converted into an active drug, we call it PALI-0008, in the terminal ileum and colon when it gets exposed to high concentrations of beta-glucuronidase. We are trying to obviously maintain a better balance between systemic and tissue concentrations. Like I said, the upper GI tract exposure is what triggers diarrhea, but it is then when you have high spikes in concentration in plasma that you get the other side effects of nausea, vomiting, and headache.
Our phase I results demonstrated that we were able to achieve IC90 steadily in plasma while maintaining like seven times the concentration in local tissues. We think that shows that the drug is behaving as it was originally intended.
Yep. Then maybe if we could walk through the phase I data, both from the healthy volunteer perspective and then more crucially in the UC and then the fibrostenotic Crohn's cohort, and sort of how that adds some more de-risking to the profile here.
Sure, yeah. We've conducted a phase I SAD, MAD, and food effect study. We've also conducted a five-patient translational ulcerative colitis study in moderate to severe patients, and then a five -over-one-week study, and then a five-patient fibrostenotic Crohn's study over two weeks. In the normal healthy studies, and treated over 100 patients have been exposed to the drug. In the normal healthy studies, we were able to push single dosing and multiple dosing pretty significantly. We demonstrated that the drug should be given once daily and that the drug should be given in the fed state. We took the max tolerable dose for our SAD, MAD, food effect study into a five-patient ulcerative colitis study. We treated patients for one week. PDE4s are extremely fast-acting drugs. We saw 100% response and 40% remission after just one week of treatment. That's by modified Mayo score.
We also saw that biomarkers confirmed this. Objective biomarkers saw a 70% reduction in PDE4B, a 30% improvement in cyclic AMP, the PD biomarker, a 70% reduction in fecal calpro, 15% in CRP. So, improvements in different biomarkers, different tissues and samples, and different types of objective measures. In the Crohn's study, we went with our once-daily dosing at 20, 25, and 30 mg. We saw two adverse events in the entire study over two weeks, discomfort and fatigue. We saw a 40% response, 40% remission by SES-CD score, a 4-point reduction from a baseline of eight, basically. Then again, biomarkers that supported that improvement in SES-CD score.
Yep. Maybe you could speak to the kind of speed of onset here and why you think one- and two-week studies are sufficient for, like, a de-risking perspective, and why you could be confident in the signal.
Sure. Historically, biomarkers like fecal calpro or hs-CRP, which are surrogate-like biomarkers in IBD, have been shown to improve with PDE4 inhibition. The apremilast study, Silvio's study on apremilast, demonstrated similar changes in fecal calpro and CRP at two weeks. The S1P data clearly shows improvements in lymphocyte count of 30% plus after a week, so those data are very similar. There's symptomatic improvement with intracellular-acting drugs, so PDE4, like a JAK inhibitor, acts on intracellular pathways.
Yeah
not just an extracellular sort of blocking mechanism or trafficking mechanism. I think that's the real reason why the onset of symptomatic improvement is so swift with PDE4.
Then maybe on the safety or tolerability side, have you seen enough data to be confident in that element of the differentiation profile as well?
We've exposed over 100 patients, some of them pretty recalcitrant to treatment, and we've treated patients on background therapy, including biologics, including standard of care like five-ASA or low-dose steroids. So a fair number of patients and a breadth in terms of length of treatment. A lot of the adverse effects with PDE4s are seen in the first three days, and there's tachyphylaxis or accommodation. So we see more adverse events in the first 48 to 72 hours, and those are usually those kinds of complaints by patients that you don't really see at later time points. So we feel like the early evaluation of safety and tolerability is sufficient.
Yep. Then can you sort of talk about why you've decided now to move into Crohn's more broadly versus FSCD after that proof-of-concept study?
Yeah. As you know, FSCD is a more difficult-to-treat population. After just two weeks of treatment, we were able to demonstrate pharmacodynamic target engagement, as Mitch mentioned, along with encouraging early endoscopic scoring. PDE4 inhibition is, as we know, both anti-inflammatory and anti-fibrotic, which works well in the broader Crohn's population as well. Moderate to severe Crohn's is a larger patient population than FSCD. It has a much better-established regulatory pathway, which was one of the keys to our decision. We are still looking to pursue FSCD longer-term, but I think given the uncertainty on the regulatory pathway in the FSCD indication right now, it makes more sense for us to pursue broader Crohn's and then go back to that. Our ASCENTRA-CD study is a 60-patient open-label study.
Yeah
where the primary endpoint is going to be centrally read endoscopic response at the end of 12 weeks.
Yep. Yeah, so maybe let us pivot to the phase II in UC. I think maybe the first question before we talk about the design specifically is just your confidence in dose selection. You looked at BID doses in the UC proof of concept and some QD dosing in the Crohn's study. What is your target coverage, and how confident are you that you are going to get there with these doses in UC?
We spent a lot of time translating this. Obviously, we did the single ascending dose, multiple ascending dose, the food effect study. We did two studies, one in UC and FSCD. We have done popPK modeling. So the popPK modeling suggested a single-dose target of between 15 and 30 mg. We took 20, 25, and then 30 into our FSCD study and showed systemically all of those patients achieved IC90, and in tissue, in the ileum, in the ascending, in the descending colon, we had seven times that drug in tissue, and so 12 times at 15 mg and 20 times IC90 in tissue at the higher dose. We also did a target phase II dosing study at 15, 30, and 45. At 45, we started to sort of see diminishing returns in terms of drug concentration in tissue.
At lower doses, like at 15 and 30, we saw that all of those patients achieved IC90. At 45 as well, but at 15 and 30, all patients achieved systemic IC90. Our target dose at 15, the mean systemic dose, the mean systemic concentration is IC90, and tissue, 100% of patients achieve IC90. At the 30 mg dose, what we consider our high dose, over 90% of patients will achieve IC90 systemically and will have 20 times IC90 in tissue.
Okay. Maybe let's move into the specific design of the UC study. It seems like not really any surprises here, a pretty standard phase II design.
Yeah, it's sort of gold standard. We have 204 patients. We have our target dose of 15, the high dose of 30 versus placebo, randomized one-to-one, a 12-week induction period, a treat-straight-through design out to 48 weeks in maintenance. The study's powered with the assumption of a 12.5-point remission rate in the placebo, and we have a 90% power to see a 20% difference, and 80% to see a 17.5% difference. I think this study is fairly conservatively powered, and again, moderate to severe patients, 50% of patients will be bio-naive.
And 50% will have seen advanced therapies.
Let's talk a little about site selection, sort of other strategies, patient selection to mitigate placebo impacts in UC, which those issues happen from time to time. What other elements of trial conduct are you focused on here?
Patient education is one. The patient population itself, the higher the advanced therapy experience, the lower the placebo remission rate. In Eastern Europe in particular, patient education so that patients don't use off-label steroids, as an example. We're working with leading CROs and patient engagement specialists to make sure that patients and sites are educated on that.
Yep. If you start dosing patients now, guidance of data in the fourth quarter of next year, can you talk about progress here and your confidence in actually getting to data this time next year?
Yeah. It's obviously early on, but so far we're tracking on plan. As Mitch mentioned, we have world-class CRO. PSI is our CRO, arguably one of the best IBD enrollment CROs in the industry. We've supplemented them with a company called Iterative Health, who is an enrollment specialist. They have 30 captive enrollment sites in the U.S., and then they have another dozen or so in Europe. Their job is to really work with the CRO to end up enhancing the enrollment process, and also getting, like Mitch was mentioning, making sure you're getting the right patients.
Yep
getting them properly educated. We're going to provide meaningful updates as appropriate, but right now our focus is on executing the studies. We've built a world-class team internally to execute on this, and so we're very optimistic that we'll be able to report top line by end of next year.
You've talked a little bit about site activation globally. Can you kind of lay out where that stands?
Sure. On the UC program, we're targeting approximately 115 sites total. That's for recruiting the 204 patients. Screen fail rates estimates are around 40%. We have 30 sites planned in the U.S., 29 of which are activated.
Site activation is the best way to sort of predict-
Yeah
patient enrollment. We have announced first patient enrolled. We have obviously the IND in the U.S., CTA approval in Canada with site activations coming, and CTA approval in the Republic of Georgia with site activations coming soon.
Europe will open up with obviously Poland being a very good enroller, and Eastern Europe and then Western Europe as well. We have a number of KOLs that have said, even at recent conferences, that they love our program, they love our team, and lots of folks that are interested in joining the program and enrolling patients.
Yeah, so maybe, obviously there is a lot going on in IBD generally right now. Is it competitive at sites? How is the competitive site landscape looking right now with all of the other clinical trials that are going on?
It is competitive. We have measures, we will keep that as know-how, but we have measures to make it less-
Yep
competitive, who we are working with, and the agreements that we have made.
With that, thinking into the future, where do you see 2108, the PDE4 class fitting into the UC landscape? Is it a monotherapy early? Is it combinations? How are you thinking about the class in 2108?
Yeah, so initially we are developing it as a monotherapy. We think it has the potential to be best in class as just a monotherapy. Quite frankly, you really cannot even start talking about combination strategies until you first prove
Sure
your drug as a monotherapy. There still is a substantial unmet need in IBD for better efficacy with generally in the mid-20s and below is the current standard. I think combinations will help. Our drug hopefully will help, we will get beyond that, but then combining with other good strategies
will help too. I think also the convenience of oral therapies
That's right.
are a major focus right now. You've got J&J with their IL-23, you've got Gilead with an oral integrin, Abivax has got their miR-124. The good thing about our drug is that, as Mitch mentioned, you're seeing early signs of relief. I think that gives us an ability to possibly be used earlier on in the treatment
regimen to provide quicker symptomatic relief for patients.
Is there a mechanism that you think makes the most sense to combine with PDE4?
We are doing a fair bit of work so that we can educate ourselves and be experts as to PDE4 combos. We're working with AI-supported computer learning model that's been trained on over 7,000 patient data and validated, as well as organoid data, as well as micro-dissected epithelial-type data. We have a deep understanding of how PDE4A, B, and D work. B sort of more the inflammatory component, A and D sort of epithelia and stroma. We feel that the model is telling us that we can get close to 100% gene network coverage, which would result in molecular remission. There's symptomatic remission, endoscopic remission, histologic now. We're talking about molecular remission. We're using that model to explore and understand our combo partners.
Yep
that we can engage meaningfully with partners.
Yep. Yep. Is that something that you feel like you'd pursue on your own, or is that a partnership opportunity potentially?
I think really either.
Yep.
Right? I mean, it sort of depends. I mean, as you know, our focus right now is
Sure
the monotherapy studies.
As it should be.
But we'll be opportunistic, right? At some point, I think it will make sense for us to, as we move into phase III, for example, it would make sense for us to start exploring our own combo-
Yeah
studies. But we're also getting inquiries from corporate on possibly doing something with them as well.
Yeah, and we're doing our homework. I mean, we're doing the formulation work to understand how to do the CMC sort of drug product co-formulation, if that's of interest.
Interesting. Okay. Maybe let's talk about the ASCENTRA-CD study design in particular. I think, JD, you talked about it at a high level, but maybe the first question is sort of why an open-label study?
Yeah, I think there's good precedent from a technical perspective. Enrolling patients in an open-label study, you get to offer, 100% of patients get exposed to drug, in this case, a high dose of 30 mg. There's a precedent with, I think, Prometheus with a Merck acquisition, but also Merck used the Crohn's data to go directly into a phase III program of 1,200 patients. I think both from a technical perspective and from a level of evidence required to move on to later stages of development, we feel that the 60-patient open-label Crohn's program should provide us enough evidence to move into a phase III.
How's progress looking there?
Making very good progress. We have obviously the INDs cleared, and we have a number of different ongoing regulatory interactions. The first geographies of approvals will be in the U.S. and probably the Republic of Georgia, and then we'll open up Europe after that. We're expecting there to be site activations
before the end of the year.
Will it be significant site overlap with UC or no?
I think we would have thought maybe there'd be more even site overlap. I would say there's more than 50% site-
Okay
more than 50% site overlap. But we're really looking for the sites that are most passionate about Crohn's patients-
Yep
that have interest in PDE4s and want to enroll patients in our study. We didn't only specifically look for sites that were overlapped.
Okay. In terms of what data disclosure looks like here, obviously, this is an open-label study, so there is some flexibility, but what is kind of the quantum of data that you would want to generate before you share with the street?
You want to take that?
Yeah. We have looked at this a number of different ways. We have tried to We are still looking at it.
Yeah
As to whether or not we are going to get early symptomatic data. Obviously, the study is going to be open label. We think that you would want to get a meaningful cohort of patient data through 12 weeks.
It's unclear whether or not that will come in Q3 next year. It's kind of unclear as to the timing of that.
We're going to have to spend some more time with the early enrollment data. We think it's possible that the Crohn's study will enroll well.
Yeah.
Obviously, we're guiding to a Q1 2028 top-line readout, but it could be that the open-label nature of the study and what the site investigators are seeing encourages them, and they could enroll the study more quickly.
Well, the fact that there is no placebo, I think.
Sure
will help with enrollment as well.
Yep. Yep. Then maybe a final question here. Just what is your current cash runway, and what is embedded in those assumptions?
Sure. We just released our third quarter 10-Q last night. We reported just under $115 million of cash, no debt still on the balance sheet, very clean balance sheet. We have enough cash to get through the readouts of both the UC and the CD studies, and also get through a good amount of the phase III readiness between now and then.
Great. Well, JD, Mitch, thanks so much.
Thanks.
Thanks for having us, Alex.
Yep.